GeneDx Holdings WGS
GeneDx Holdings reported a net loss of $12.33 million
GeneDx Holdings (WGS) filed a 10-Q with the SEC on Nov 9, 2026, 4:17 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001628280-26-072203
- Revenue: $123.1 million for the three months ended Sep 30, 2026
- Net loss: $12.33 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.41 for the three months ended Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor · 1 new legal mention
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $123.1M | $114.44M | +7.6% |
| Operating income and margin | −$10.43M · -8.5% | −$17.46M · -15.3% | +40%, margin +6.8 pts |
| Net income | −$12.33M | −$17.74M | +31% |
| Operating cash flow | −$10.6M | −$28.98M | +63% |
| Cash | $96.14M | $60.32M | +59% |
New risk factors (1)
- We face uncertainty related to healthcare reform, pricing, coverage and reimbursement, which could reduce our revenue. +4 more paragraphs
New legal mentions (1)
- The Company is unable to predict the outcome of these actions or to estimate the reasonably possible loss or range of loss, if any, at this time.